# Patent

## Title
Small molecule inhibitors of necroptosis

## Abstract

Compounds having the following structure (VI-A):




or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, wherein RE1, RE2, RE3, RE4, ZE2 and ZE3 are as disclosed herein, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating disorders associated with necrosptosis are also provided.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 13/141,545, filed Sep. 9, 2011, which is the U.S. National Stage of International Application No. PCT/US2009/069483, filed Dec. 23, 2009, which claims benefit of U.S. Provisional Application No. 61/140,615, filed Dec. 23, 2008, each of which is hereby incorporated by reference.


STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
This invention was made with government support under UO1 NS050560 awarded by the National Institutes of Health. The U.S. government has certain rights to this invention.


FIELD OF THE INVENTION
The invention relates to compounds and to cell death, in particular through necrosis and necroptosis, and regulation thereof by small molecules.
BACKGROUND OF THE INVENTION
In many diseases, cell death is mediated through apoptotic and/or necrotic pathways. While much is known about the mechanisms of action that control apoptosis, control of necrosis is not as well understood. Understanding the mechanisms regulating both necrosis and apoptosis in cells is essential to being able to treat conditions, such as neurodegenerative diseases, stroke, coronary heart disease, kidney disease, and liver disease. A thorough understanding of necrotic and apoptotic cell death pathways is also crucial to treating AIDS and the conditions associated with AIDS, such as retinal necrosis.
Cell death has traditionally been categorized as either apoptotic or necrotic based on morphological characteristics (Wylie et al., Int. Rev. Cytol. 68: 251 (1980)). These two modes of cell death were also initially thought to occur via regulated (caspase-dependent) and non-regulated processes, respectively. More recent studies, however, demonstrate that the underlying cell death mechanisms resulting in these two phenotypes are much more complicated and, under some circumstances, interrelated. Furthermore, conditions that lead to necrosis can occur by either regulated caspase-independent or non-regulated processes.
One regulated caspase-independent cell death pathway with morphological features resembling necrosis, called necroptosis, has recently been described (Degterev et al., Nat. Chem. Biol. 1:112 (2005)). This manner of cell death can be initiated with various stimuli (e.g., TNF-α and Fas ligand) and in an array of cell types (e.g., monocytes, fibroblasts, lymphocytes, macrophages, epithelial cells and neurons). Necroptosis may represent a significant contributor to and, in some cases, predominant mode of cellular demise under pathological conditions involving excessive cell stress, rapid energy loss, and massive oxidative species generation, where the highly energy-dependent apoptosis process is not operative.
The identification and optimization of low molecular weight molecules capable of inhibiting necroptosis will assist in elucidating its role in disease patho-physiology and could provide compounds (i.e., necrostatins) for anti-necroptosis therapeutics. The discovery of compounds that prevent caspase-independent cell death (e.g., necrosis or necroptosis) would also provide useful therapeutic agents for treating or preventing conditions in which necrosis occurs. These compounds and methods would be particularly useful for the treatment of neurodegenerative diseases, ischemic brain and heart injuries, and head trauma.
SUMMARY OF THE INVENTION
The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
In a first aspect, the invention features a compound having a structure according to the following formula:




where

each RH1, RH2, RH3, RH4, RH5, RH10, RH17, XH2, Z1, ZH2, and n is as defined for Formula (I),
XH2 is selected, independently, from O, S, or NRH9;
each RH1, RH2, RH3, RH4, and RH5 is selected, independently from H, halogen, cyano, nitro, azido, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C(═O)RH12, —C(═O)ORH12, —C(═O)NRH12RH13, —C(═S)RH12, —C(═S)NRH12RH13, —C(═NRH14)RH12, —C(═NRH14)NRH12RH13, or —[ZH1—(CRH15RH16)n—{C(═XH2)}n—ZH2—R17], or RH1 and RH3 combine to form a carbon-carbon double bond;
each ZH1 and ZH2 is selected, independently, from a single bond, O, S, or NRH11;
each RH9, RH10, RH11, RH12, RH13, RH14, RH15, RH16, and RH17, is selected, independently from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
n is an integer between 0-6; and
o is 0 or 1; and
when RH1 is H, RH2 is H or CO2Me, RH3 is H, RH4 is unsubstituted phenyl or phenyl substituted with 1, 2, or 3 substituents selected from methoxy, chloro, or fluoro, RH5 is CN, RH10 is H, ZH1 is S, n is 1, XH2 is O, and ZH2 is NH, RH17 is not H, methyl, methoxy, unsubstituted 2-thiazolyl, unsubstituted phenyl, 4-methoxyphenyl, 4-methylphenyl, 2-ethoxyphenyl, 4-isopropylphenyl, 4-fluorophenyl, or 2,4,6-trimethylphenyl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, the compound has a structure according to Formula (I-B)




where

each RH1 and RH3 is selected, independently, from H, halogen, cyano, nitro, azido, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C(═O)RH12, —C(═O)ORH12, or —C(═O)NRH12RH13, or RH1 and RH3 combine to form a carbon-carbon double bond;
each RH4 and RH17 is selected, independently, from optionally substituted aryl or optionally substituted heteroaryl;
RH5 is selected from H, CN, —C(═O)ORH12, or —C(═O)NRH12RH13;
each RH10, RH11, RH12, and RH13 is selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
ZH1 is selected from a single bond or S;
ZH2 is selected from a single bond or NRH11; and
XH2 is O or S;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In other embodiments, the compound has the following structure:




or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RH1 and RH3 are H.
In some embodiments, RH5 is CN.
In some embodiments, RH10 is H.
In some embodiments, ZH1 is S.
In some embodiments, ZH2 is NH,
In some embodiments, RH4 is unsubstituted phenyl or phenyl having 1, 2, 3, 4, or 5 substituents. In further embodiments, the phenyl includes 1, 2, or 3 substituents selected from F, Cl, or ORH18, where each RH18 is, independently, selected from H or optionally substituted C1-6 alkyl. In certain embodiments, the phenyl is 2-fluorophenyl, 2-chlorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3,4,5-trimethoxyphenyl, or 3,4-dimethoxyphenyl.
In some embodiments, RH17 is optionally substituted heteroaryl. In certain embodiments, heteroaryl selected from furan, thiophene, pyrrole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,3-oxadiazole or 1,2,5-oxadiazole, oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, 1,2,4-triazole, 1,2,3-triazole, benzotriazole, pyridine, pyrimidine, pyrazines, quinoline, isoquinoline, purine, pyrazine, pteridine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, indole, 1,2,4,5-tetrazine, benzo[b]thiophene, benzo[c]thiophene, benzofuran, isobenzofuran, and benzimidazole.
In a second aspect, the invention features a compound having a structure according to the following formula




where

each RA1, RA3, and RA4 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RA1 and RA4 combine to form a carbon-carbon double bond;
GA2 is absent or —(CRA11RA12)n—;
XA3 is absent or is O, S, or NRA8;
each RA8 and RA13 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CORA14, —CO2RA14, or —CONRA14RA15;
each RA9, RA10, RA11, and RA12 is selected, independently, from H, halogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RA7, RA14 and RA15 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
each m and n is, independently, 1, 2, or 3; and
where when one of RA1 and RA4 is H and the other is selected from H or CO2Et, and RA3 is unsubstituted phenyl, GA2-XA3—RA7 is not NHC6H5, NH(p-C6H4F), NH(p-C6H4OH), NH(p-C6H4OMe), NH(3-OH-4-C1-C6H4), —CH2(O-p-C6H4Me), —CH2(4-ethylpiperazinyl), —CH2S(2-phenyltetrazolyl), —CH2S(4-chlorophenyl), —CH2S(2-benzothiazolyl), —CH2S(2-(N-methylimidazolyl)), —CH2S(4,6-dimethylquinazolinyl), adamantyl, or optionally substituted oxiranyl; and
where when RA1 and RA4 are each H and RA3 is 4-methoxyphenyl, GA2-XA3—RA7 is not optionally substituted oxiranyl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RA1 and RA4 are H.
In some embodiments, RA3 is unsubstituted phenyl.
In some embodiments, RA3 is phenyl having 1, 2, 3, 4, or 5 substituents.
In some embodiments, GA2 is absent.
In certain embodiments, XA3 is absent and RA7 is optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In other embodiments, XA3 is NRA8 and RA7 is optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments, GA2 is CH2.
In some embodiments, XA3 is S and RA7 is optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments, XA3 is absent and RA7 is optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In a third aspect, the invention features compounds according to the following formula




where

each RA1, RA2, RA4, and RA6 is selected, independently, from H, —C(═O)—XA3—RA7, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RA1 and RA4 combine to form a carbon-carbon double bond;
each XA3 is, independently, absent, —O—, or —NRA8—,
each RA8 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CORA14, —CO2RA14, or —CONRA14RA15;
each RA7, RA14 and RA15 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
wherein when RA1 and RA4 combine to form a carbon-carbon double bond and RA2 is H, RA6 is not 4-chlorophenyl, 4-methoxyphenyl, or 4-(NHCO2tBu)phenyl; and
where when RA1 is H, RA4 is H or CO2Et, RA2 is unsubstituted phenyl, RA6 is not —C(═O)-(unsubstituted phenyl) or —C(═O)-(4-methylphenyl); and
where when RA1 is H, RA4 is —C(═O)-(unsubstituted phenyl), RA2 is 4-chlorophenyl, RA6 is not CO2Et;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RA5 is H; each RA1, RA2, RA4, and RA6 is selected, independently, from H, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)—XA3—RA7, or RA1 and RA4 combine to form a carbon-carbon double bond; each RA7 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each XA3 is, independently, absent, —O—, or —NRA8—,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In certain embodiments, RA1 and RA4 combine to form a carbon-carbon double bond.
In other embodiments, RA6 is optionally substituted aryl or optionally substituted heteroaryl.
In some embodiments, RA6 is a phenyl group having a substituent at the 4-position.
In certain embodiments, RA1 and RA4 are each H, RA2 is optionally substituted aryl or optionally substituted heteroaryl, and RA6 is —C(═O)—XA3—RA7.
In other embodiments, RA2 is unsubstituted phenyl.
In a fourth aspect, the invention features a compound having a structure according to the following formula:




where

RB1 is selected from H, optionally substituted C1-6 alkyl, —C(═O)RB18, —C(═O)ORB18, or —C(═O)NRB18RB19;
RB2 is selected from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or optionally substituted C2-6 alkynyl;
each RB3 and RB4 is selected, independently from H, optionally substituted C1-6 alkyl, or RB3 and RB4 combine to form a bridging group having the structure —(CH2)n—(CRB13═CRB14)o—(CH2)p—;
each n, o, and p is, independently, 0 or 1;
each RB5, RB6, RB7, RB8, RB9, RB10, RB11, and RB12 is selected, independently, from H, halogen, —CN, —NO2, —N3, —RB13, —ORB13, —SRB13, —NRB13RB14, —C(O)RB15, —C(═O)ORB15, —C(═O)NRB15RB16, —OC(═O)RB15, —OC(═O)ORB15, —OC(═O)NRB15RB16, —NRB15C(═O)RB15, —NRB15C(═O)ORB16, —NRB15C(═O)NRB16RB17, —C(═S)RB15, —C(═S)NRB15RB16, —NRB15C(═S)RB16, —NRB15C(═S)NRB16RB17, —C(═NRB13)NRB15RB16, —NRB15C(═NRB13)RB16, —NRB15C(═NRB13)NRB16RB17;
each RB13 and RB14 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)RB18, —C(═O)ORB18, or —C(═O)NRB18RB19,
each RB15, RB16, RB17, RB18, and RB19 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
where when each n, o, and p is 0, RB3 and RB4 combine to form a single bond, and
where RB1 is not H or CH3 when RB5, RB6, RB7, RB8, RB9, RB10, RB11, and RB12 are each H, RB2 is ethyl, ethenyl, 2-haloethenyl, ethynyl, haloethynyl, propynyl, or —C≡C—C(OH)(CH3)2, and when RB3 and RB4 are each H or combine to form a bond, —CH2CH2— or —CH═CH—;
where RB1 is not H when RB5, RB6, RB7, RB8, RB10, and RB11 are each H, at least one of RB9 or RB12 is fluoro, RB2 is ethynyl, and when RB3 and RB4 combine to form —CH2CH2—;
wherein RB1 is not H when RB5, RB7, RB9, and RB11 are H and one or two of RB6, RB8, RB10, and RB12 is halogen, nitro, or methyl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RB1 is H.
In some embodiments, RB2 is C1-3 alkyl.
In certain embodiments, RB2 is C1-3 alkenyl.
In other embodiments, RB2 is ethynyl.
In some embodiments, RB3 and RB4 are each H.
In certain embodiments, the compound has the following structure




where

RB2 is ethyl, ethenyl, or ethynyl and each RB9, RB10, RB11, and RB12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof. In some embodiments, RB10 or RB12 is fluoro.

In some embodiments, the compound has the following structure:




where

RB2 is ethyl, ethenyl, or ethynyl and each RB9, RB10, RB11, and RB12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In a fifth aspect, the invention features a structure according to the following formula




where

each RC1, RC2, and RC3 is selected, independently, from H, optionally substituted C1-6 alkyl, —Y—RC7, or RC1 and RC2 combine to form a (═O) or a (═S) group, or RC1 and RC3 combine to form a carbon-nitrogen double bond;
RC4 is selected from H, halogen, —CN, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or —C(═O)ZRC8,
each RC5 and RC6 is selected, independently, from H, optionally substituted C1-6 alkyl, or RC5 and RC6 combine to form an optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RC7, RC8, RC9, RC10, RC11, and RC12 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
X is —CRC11═CRC12—, O, S, or NRC9;
Y is, independently, a single bond, (CRC8RC9)n, O, S, or NRC10; and
Z is a single bond, O, S, or NRC10;
n is an integer between 0-4; and
where when X is S, RC1 and RC2 combine to form a (═O) group, RC4 is H, and RC5 and RC6 combine to form unsubstituted cyclopentyl, RC3 is not —CH2—RC7, where RC7 is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted 8-quinolyl, unsubstituted 2-oxoquinolyl, or phenyl having 1 or 2 substituents selected from F, OMe, Me, CN, or Cl; and
wherein when X is S, RC1 and RC2 combine to form a (═O) group, RC4 is H, and RC5 and RC6 are each CH3, RC3 is not —CH2—RC7, where RC7 is unsubstituted phenyl; and
where when X is CH═CH, RC1 and RC2 combine to form a (═O) group, RC4 is H, and RC5 and RC6 are H, RC3 is not —CH2(4-halophenyl);
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, each RC5 and RC6 is optionally substituted C1-6 alkyl.
In other embodiments, the compound has a structure according to the following formula:




wherein X, RC1, RC2, RC3, and RC4 are as defined for Formula (IV) and n is an integer between 0-3,

or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RC1 and RC7 combine to form a (═O) group.
In other embodiments, X is S.
In some embodiments, n is 1.
In certain embodiments, RC3 is —Y—RCS.
In other embodiments, RC3 is —(CH2)-(optionally substituted aryl).
In a sixth aspect, the invention features a compound having a structure according to the following formula




where

each YD1 and YD2 is selected, independently, from —C(═O)— or —S(═O)2—;
A is phenyl having 0, 1, 2, 3, or 4 additional substituents;
RD2 and RD3 are selected, independently from H, halogen, CN, NC, N3, NO2, —CORD13, —CO2RD11, —CONRD13RD14, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RD5, RD9, RD10, RD13, and RD14 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RD9 and RD10 combine to form a heterocyclyl; and
where when RD2, RD3, and RD5 are H, YD1 is —(C═O)—, YD2 is —(SO2)—, and RD9 and RD10 are each ethyl or RD9 is methyl and RD10 is CH2(2-tetrahydrofuran), and A is phenyl having 0 additional substituents, YD1 and YD2 are not para to each other,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, YD1 and YD2 are ortho or meta to each other.
In other embodiments, YD1 and YD2 are para to each other.
In some embodiments, the compound has a structure according to the following formula




where

each RD2, RD3, RD17, RD18, RD19, and RD20, is selected, independently from H, halogen, CN, NC, N3, NO2, —CORD13, —CO2RD13, —CONRD13RD14, optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each RD9 and RD10 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, or optionally substituted aryl, or RD9 and RD10 combine to form a heterocyclyl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RD17, RD18, RD19, and RD20 are H.
In some embodiments, RD2 and RD3 are H.
In other embodiments, RD9 and RD10 are each optionally substituted C1-6 alkyl.
In a seventh aspect, the invention features a compound having a structure according to




where

each ZE2 and ZE3 is selected, independently, from a single bond, —(CRE6RE7)n—, —C(═O)—, or RE1 and ZE2—RE2 combine to form a double bond;
each RE1, RE2, and RE4 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
RE3 is selected from optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RE6 and RE7 is selected, independently, from H or optionally substituted C1-6 alkyl; and
each n is an integer between 1-6; and
where when RE1 and RE4 are H, ZE2 and ZE3 are each CH2, and RE2 is unsubstituted 3-indolyl, RE3 is not 4-chlorophenyl or CH2CH2O(p-C6H4F),
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, the compound has a structure according to




where

RE3 is optionally substituted aryl or optionally substituted heteroaryl; and
R9 is H, halogen, CN, NO2, OR13, NR13R14, COR15, CO2R15, or optionally substituted C1-6 alkyl;
each R13 and R14 is selected, independently, from H, COR16, CO2R16, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and,
each R15 and R16 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RE3 is optionally substituted aryl.
In some embodiments, RE3 is unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl.
In other embodiments, RE3 is substituted C3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl. In other embodiments, the substituted C3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl includes 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N3, —OR′, —NR′C(═O)R′′, —C(═O)NRR′, —NRR′, —OC(═O)NR′R′′, —NRC(═O)OR′, —OH, and —NC), wherein each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
In still other embodiments, RE3 is substituted aryl or substituted heteroaryl. In some embodiments, RE3 is substituted phenyl. In some embodiments, the substituted phenyl is substituted with at least one halogen. In other embodiments, the substituted phenyl is substituted with 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N3, —OR′, —NR′C(═O)R′′, —C(═O)NRR′, —NRR′, —OC(═O)NR′R′′, —NRC(═O)OR′, —OH, and —NC), wherein each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
In some embodiments, the stereocenter marked by the asterisk in the compound of Formula (VI) has the (R)-configuration. In other embodiments, the stereocenter marked by the asterisk has the (S)-configuration.
In any of the embodiments described herein, one or both of —ZE3 and RE3 does not include substituents selected from the group consisting of: halogen (e.g., F, Cl, Br, or I); nitro (—NO2), cyano (—CN), acyloxy(═OC(═O)R′), acyl (—C(═O)R′), carboxylic acid (—CO2H), carboxylic ester (—CO2R′), sulfonate (—S(═O)2OR), sulfonamide (—S(═O)2NRR′ or —NRS(═O)2R′), or sulfonyl (—S(═O)2R), where each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, as described herein.
In an eighth aspect, the invention features a compound having a structure according to the following formula,




where

ZF1 is selected from a single bond, —(CH2)—, —C(═O)—, or —S(═O)2—;
RF1 is selected from H, ORF14, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
RF2 and RF4 are each H, or RF2 and RF4 combine to form a carbon-carbon double bond;
each RF6, RF7, RF8, and RF9 is selected, independently, from H, halogen, CN, NC, N3, NO2, ORF12, SRF12, NRF12RF13, —CORF12, —CO2 F12, —CONRF12RF13, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each RF12, RF13, and RF14 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
where when RF2, RF4, RF6, RF7, RF8, and RF9 are each H and ZF1 is —C(═O)—, RF1 is not -(unsubstituted 1,4-benzodioxane) or —CH2—O-(unsubstituted phenyl), or —CH(CH3)O(o-tolyl);
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RF2 and RF4 are each H.
In other embodiments, RF6, RF7, RF8, and RF9 are H.
In certain embodiments, ZF1 is —C(═O)—. In further embodiments, RF1 is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In a ninth aspect, the invention features a compound having a structure according to the following formula




where

each RG1, RG2, RG5, and RG6 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RG1 and RG2, or RG5 and RG6 combine to form an optionally substituted cycloalkyl or heterocyclyl; and
where when RG1 is unsubstituted phenyl and RG2 is H, RG5 and RG6 do not combine to form unsubstituted cyclopentyl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RG1 or RG5 is phenyl having 0, 1, 2, 3, 4, or 5 substituents. In certain embodiments, RG1 is unsubstituted phenyl.
In some embodiments, RG2 or RG6 is phenyl having 0, 1, 2, 3, 4, or 5 substituents.
In other embodiments, RG1 and RG2, or RG5 and RG6 combine to form an optionally substituted cycloalkyl. In certain embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
In a tenth aspect, the invention features a pharmaceutical composition including a pharmaceutically acceptable excipient and any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
In an eleventh aspect, the invention features a method of treating a condition in a subject, with the method including the step of administering the compound of any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.
In some embodiments, the condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
In some embodiments, the condition is a neurodegenerative disease of the central or peripheral nervous system.
In some embodiments, the condition is hepatic or brain ischemic injury, or ischemic injury during organ storage, head trauma, septic shock, or coronary heart disease.
In some embodiments, the condition is stroke.
In some embodiments, the condition is myocardial infarction.
In a twelfth aspect, the invention features a method of decreasing necroptosis, where the method includes contacting a cell with any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70)), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
In a thirteenth aspect, the invention features a kit including
(a) a pharmaceutical composition comprising any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof; and
(b) instructions for the use of the pharmaceutical composition of (a) to treat a condition in a subject.
In any of the compositions, methods, and kits of the invention, the compound can be selected from the group consisting of:



















or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
By “C1-4 alkaryl” is meant a C1-4 alkyl group having an optionally substituted aryl or an optionally substituted heteroaryl located at any position of the carbon chain. The C1-4 alkyl group may be linear or branched and may also be substituted with, for example, 1, 2, 3, 4, or 5 additional substituents as described herein.
By “alkoxy” is meant a group having the structure —O(optionally substituted C1-6 alkyl), where the optionally substituted Ch6 alkyl may be branched, linear, or cyclic. The C1-6 alkyl may be substituted or unsubstituted. A substituted C1-6 alkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position. Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, and the like.
By “C2-6 alkenyl” or “alkenyl” is meant an optionally substituted unsaturated C2-6 hydrocarbon group having one or more carbon-carbon double bonds. Exemplary C2-6 alkenyl groups include, but are not limited to —CH═CH (ethenyl), propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. A C2-6 alkenyl may be linear or branched and may be unsubstituted or substituted. A substituted C2-6 alkenyl may have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position.
By “C1-6 alkyl” or “alkyl” is meant an optionally substituted C1-6 saturated hydrocarbon group. An alkyl group may be linear, branched, or cyclic (“cycloalkyl”). Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like, which may bear one or more substitutents. Substituted alkyl groups may have, for example, 1, 2, 3, 4, 5, or 6 substitutents located at any position. Exemplary substituted alkyl groups include, but are not limited to, optionally substituted C1-4 alkaryl groups.
By “C2-6 alkynyl” or “alkynyl” is meant an optionally substituted unsaturated C2-6 hydrocarbon group having one or more carbon-carbon triple bonds. Exemplary C2-6 alkynyl groups include, but are not limited to ethynyl, 1-propynyl, and the like
By “amino” is meant a group having a structure —NR′R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl. When R′ is not H or R′′ is not H, R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “aryl” is meant is an optionally substituted C6-C14 cyclic group with [4n+2]π electrons in conjugation and where n is 1, 2, or 3. Non-limiting examples of aryls include heteroaryls and, for example, benzene, naphthalene, anthracene, and phenanthrene. Aryls also include bi- and tri-cyclic ring systems in which a non-aromatic saturated or partially unsaturated carbocyclic ring (e.g., a cycloalkyl or cycloalkenyl) is fused to an aromatic ring such as benzene or napthalene. Exemplary aryls fused to a non-aromatic ring include indanyl, tetrahydronaphthyl. Any aryls as defined herein may be unsubstituted or substituted. A substituted aryl may be optionally substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position of the ring.
By “aryloxy” is meant a group having the structure —O(optionally substituted aryl), where aryl is as defined herein.
By “azido” is meant a group having the structure —N3.
By “carbamate” or “carbamoyl” is meant a group having the structure —OCONR′R′′ or —NR′CO2R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl. When R′ is not H or R′′ is not H, R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “carbonate” is meant a group having a the structure —OCO2R′, where R′ is selected from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. When R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “carboxamido” or “amido” is meant a group having the structure —CONR′R′′ or —NR′C(═O)R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl. When R′ is not H or R′′ is not H, R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “carboxylic group” is meant a group having the structure —CO2R′,
where R′ is selected from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. When R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “cyano” is meant a group having the structure —CN.
By “C3-10 cycloalkyl” or “cycloalkyl” is meant an optionally substituted, saturated or partially unsaturated 3- to 10-membered monocyclic or polycyclic (e.g., bicyclic, or tricyclic) hydrocarbon ring system. Where a cycloalkyl is polycyclic, the constituent cycloalkyl rings may be fused together, form a spirocyclic structure, or the polycyclic cycloalkyl may be a bridged cycloalkyl (e.g., adamantyl or norbonanyl). Exemplary cycloalkyls induce cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Cycloalkyls may be unsubstituted or substituted. A substituted cycloalkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “cycloalkenyl” is meant a non-aromatic, optionally substituted 3- to 10-membered monocyclic or bicyclic hydrocarbon ring system having at least one carbon-carbon double bound. For example, a cycloalkenyl may have 1 or 2 carbon-carbon double bonds. Cycloalkenyls may be unsubstituted or substituted. A substituted cycloalkenyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents. Exemplary cycloalkenyls include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, and the like.
By “effective amount” or “therapeutically effective amount” of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an effective amount depends upon the context in which it is being applied. For example, in the context of administering an agent that is an inhibitor of necroptosis, an effective amount of an agent is, for example, an amount sufficient to achieve a reduction in necroptosis as compared to the response obtained without administration of the agent.
By “ester” is meant a group having a structure selected from —OCOR′, where R′ is selected from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. When R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “halogen” or “halo” is meant fluorine (—F), chlorine (—Cl), bromine (—Br), or iodine (—I).
By “heteroaryl” is mean an aryl group that contains 1, 2, or 3 heteroatoms in the cyclic framework. Exemplary heteroaryls include, but are not limited to, furan, thiophene, pyrrole, thiadiazole (e.g., 1,2,3-thiadiazole or 1,2,4-thiadiazole), oxadiazole (e.g., 1,2,3-oxadiazole or 1,2,5-oxadiazole), oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, triazole (e.g., 1,2,4-triazole or 1,2,3-triazole), benzotriazole, pyridines, pyrimidines, pyrazines, quinoline, isoquinoline, purine, pyrazine, pteridine, triazine (e.g, 1,2,3-triazine, 1,2,4-triazine, or 1,3,5-triazine)indoles, 1,2,4,5-tetrazine, benzo[b]thiophene, benzo[c]thiophene, benzofuran, isobenzofuran, and benzimidazole. Heteroaryls may be unsubstituted or substituted. Substituted heteroaryls can have, for example, 1, 2, 3, 4, 5, or 6 substitutents.
By “heterocyclic” or “heterocyclyl” is meant an optionally substituted non-aromatic, partially unsaturated or fully saturated, 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size, and polycyclic ring systems (e.g., bi- and tri-cyclic ring systems) which may include an aryl (e.g., phenyl or naphthyl) or heteroaryl group that is fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, or heterocyclyl), where the ring system contains at least one heterotom. Heterocyclic rings include those having from one to three heteroatoms independently selected from oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized or substituted. In certain embodiments, the term heterocylic refers to a non-aromatic 5-, 6-, or 7-membered monocyclic ring wherein at least one ring atom is a heteroatom selected from O, S, and N (wherein the nitrogen and sulfur heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms. Where a heterocycle is polycyclic, the constituent rings may be fused together, form a spirocyclic structure, or the polycyclic heterocycle may be a bridged heterocycle (e.g., quinuclidyl or. Exemplary heterocyclics include, but are not limited to, aziridinyl, azetindinyl, 1,3-diazatidinyl, pyrrolidinyl, piperidinyl, piperazinyl, thiranyl, thietanyl, tetrahydrothiophenyl, dithiolanyl, tetrahydrothiopyranyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyranonyl, 3,4-dihydro-2H-pyranyl, chromenyl, 2H-chromen-2-onyl, chromanyl, dioxanyl (e.g., 1,3-dioxanyl or 1,4-dioxanyl), 1,4-benzodioxanyl, oxazinyl, oxathiolanyl, morpholinyl, thiomorpholinyl, thioxanyl, quinuclidinyl, and also derivatives of said exemplary heterocyclics where the heterocyclic is fused to an aryl (e.g., a benzene ring) or a heteroaryl (e.g., a pyridine or pyrimidine) group. Any of the heterocyclic groups described herein may be unsubstituted or substituted. A substituted heterocycle may have, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “ketone” or “acyl” is meant a group having the structure —COR′, where R′ is selected from H, optionally substituted C1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. When R′ is not II, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
By “nitro” is meant a group having the structure —NO2.
A “pharmaceutically acceptable excipient” as used herein refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
The term “pharmaceutically acceptable salt,” as used herein, represents those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66:1-19. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting the free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like.
The term “pharmaceutically acceptable solvates,” as used herein, refers to compounds that retain non-covalent associations to residual solvent molecules in the solid state. For example, solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof. Solvates include, but are not limited to, compounds that include solvent molecules in the crystal lattice following recrystallization. The molecular stoichiometry of solvation can vary from, for example, 1:1 solvent:compound to 10:1 solvent:compound. These ratios can include a mixture of associated solvent molecules. Exemplary, non-limiting examples of solvents that can form solvates with the compounds of the invention include water (for example, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, or any combination thereof.
By “pharmaceutical composition” is meant a composition containing a compound of the invention, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Excipients consisting of DMSO are specifically excluded. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or any other formulation described herein.
By “stereoisomer” is meant a diastereomer, enantiomer, or epimer of a compound. A chiral center in a compound may have the S-configuration or the R-configuration. Enantiomers may also be described by the direction in which they rotate polarized light (i.e., (+) or (−)). Diastereomers of a compound include stereoisomers in which some, but not all, of the chiral centers have the opposite configuration as well as those compounds in which substituents are differently oriented in space (for example, trans versus cis).
Where a group is substituted, the group may be substituted with 1, 2, 3, 4, 5, or 6 substituents. Optional substituents include, but are not limited to: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen; azido(—N3), nitro (—NO2), cyano (—CN), acyloxy(—OC(═O)R′), acyl (—C(═O)R′), alkoxy (—OR′), amido (—NR′C(═O)R′′ or —C(═O)NRR′), amino (—NRR′), carboxylic acid (—CO2H), carboxylic ester (—CO2R′), carbamoyl (—OC(═O)NR′R′′ or —NRC(═O)OR′), hydroxy (—OH), isocyano (—NC), sulfonate (—S(═O)20R), sulfonamide (—S(═O)2NRR′ or —NRS(═O)2R′), or sulfonyl (—S(═O)2R), where each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. A substituted group may have, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents. In some embodiments, each hydrogen in a group may be replaced by a substituent group (e.g., perhaloalkyl groups such as —CF3 or —CF2CF3 or perhaloaryls such as —C6F5). In other embodiments, a substitutent group may itself be further substituted by replacing a hydrogen of said substituent group with another substituent group such as those described herein. Substituents may be further substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents as defined herein. For example, a lower C1-6 alkyl or an aryl substituent group (e.g., heteroaryl, phenyl, or naphthyl) may be further substituted with 1, 2, 3, 4, 5, or 6 substituents as described herein.


DETAILED DESCRIPTION OF THE INVENTION
We have discovered a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α)-induced necroptosis. The heterocyclic compounds of the invention include, for example, compounds of Formulas (I)-(VIII), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. Still other useful necrostatins include Compounds (1)-(45). Compounds of the invention can be synthesized according to methods known in the art or by the methods provided in the examples below. Pharmaceutical compositions including the compounds of the invention are also described. The invention also features kits and methods of treatment featuring the compounds and compositions of the invention.
Compounds of Formula (I)
Certain compounds of the invention can be described by Formula (I):




where

each XH1 and XH2 is selected, independently, from O, S, or NRH9;
YH1 is selected, independently, from O, S, or NRH10;
each RH1, RH2, RH3, RH4, RH5, RH6, RH7, and RH8, is selected, independently from H, halogen, cyano, nitro, azido, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C(═O)RH12, —C(═O)ORH12, —C(═O)NRH12RH13, —C(═S)RH12, —C(═S)NRH12RH13, —C(═NRH14)RH12, —C(═NRH14NRH12RH13, or —[ZH1—(CRH15RH16)n—{C(═XH2)}o—ZH2—RH17], or RH1 and RH3, or RH5 and RH7 combine to form a carbon-carbon double bond;
each ZH1 and ZH2 is selected, independently, from a single bond, O, S, or NRH1 
each RH9, RH10, RH11, RH12, RH13, RH14, RH15, RH16, and RH17, is selected, independently from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
n is an integer between 0-6; and
o is 0 or 1;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
Certain compounds of the invention can be described by Formula (I-A):




where each RH1, RH2, RH3, RH4, RH5, RH10, RH17, XH2, ZH1, ZH2, and n is as defined for Formula (I),

or by Formula (I-B)




where

each RH1 and RH3 is selected, independently, from H, halogen, cyano, nitro, azido, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C(═O)RH12, —C(═O)ORH12, or —C(═O)NRH12RH13, or RH1 and RH3 combine to form a carbon-carbon double bond;
each RH4 and RH17 is selected, independently, from optionally substituted aryl or optionally substituted heteroaryl;
RH5 is selected from H, CN, —C(═O)ORH12, or —C(═O)NRH12RH13;
each RH10, RH11, RH12, and RH13 is selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
ZH1 is selected from a single bond or S;
ZB2 is selected from a single bond or NRH11; and
XH2 is O or S;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (I), the compound has a structure according to the following formula:




where RH4 is as according to Formula (I-A) or (I-B).

In some embodiments of Formula (I), when RH1 is H, RH2 is H or CO2Me, RH3 is H, RH4 is unsubstituted phenyl or phenyl substituted with 1, 2, or 3 substituents selected from methoxy, ethoxy, methyl, isopropyl, chloro, or fluoro, RH5 is CN, RH6 and RH8 is H, RH10 is H, XH1 is O, YH1 is NH, and RH7 is —[S—(CH2)—{C(═O)}0—ZH2—R17], ZH2—RH17 is not OCH3 or NH—RH17, where RH17 is H, unsubstituted 2-thiazolyl, unsubstituted phenyl, 4-methoxyphenyl, 4-fluorophenyl, or 2,4,6-trimethylphenyl.
Compounds of Formulas (I), (I-A), (I-B), and (I-C) can be prepared according to methods known in the art. An exemplary method of synthesis that can be used is shown in Scheme 1 and is based on protocols disclosed in Russian Chemical Bulletin, 48(12): 2308-2311 (1999) and in Chemistry of Heterocyclic Compounds, 38(10): 1269-1275 (2002). In Scheme 1, R′ and R′′ can be, for example, an optionally substituted aryl or an optionally substituted heteroaryl group. Still other substituent patterns can be obtained by variation of the thioamide starting material that is condensed with the aldehyde.




Compounds of Formula (I) (e.g., (I-A), (I-B), or (I-C)) or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Exemplary compounds useful in the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 1. Other compounds of Formula I are shown in Table 2. In some embodiments, Formulas (I), (I-A), (I-B), or (I-C) do not include any of Compounds (1)-(12).








TABLE 1





Com-



pound
Structure







(1)






 


(2)






 


(3)






 


(4)






 


(5)






 


(6)






 


(7)





















TABLE 2







 (8)






 


 (9)






 


(10)






 


(11)






 


(12)













Compounds of Formula (II)
Select compounds of the invention can be described by Formula (II)




where

each RA1, RA2, RA3, RA4, RA5, and RA6 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a group having the structure —XA1-GA1-XA2—C(═YA1)-GA2-XA3—RA7, or RA1 and RA4 combine to form a carbon-carbon double bond;
each XA1, XA2, and XA3 is, independently, absent or selected from —O—, —S—, or —NRA8—;
GA1 is absent or —(CRA9RA10)m—;
GA2 is absent or —(CRA11RA12)n—;
YA1 is O, S, or NRA13;
each RA8 and RA13 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CORA14, —CO2RA14, or —CONRA14RA15;
each RA9, RA10, RA11, and RA12 is selected, independently, from H, halogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RA7, RA14 and RA15 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
each m and n is, independently, 1, 2, or 3;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (II), when RA1 and RA4 combine to form a carbon-carbon double bond, RA2 is H, RA3 is CH3, and RA6 is CO2H, RA5 is not CH2(2-chlorophenyl).
In some embodiments of Formula (II), when RA1 and RA4 combine to form a carbon-carbon double bond, RA2 is H, RA6 is CH3 or tBu, and RA3 is NHC(═O)NHRA7, RA7 is not chlorophenyl or dichlorophenyl.
Certain compounds of Formula (II) may be described further according to Formula (II-A)




where

each RA1, RA3, RA4, and RA7 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RA1 and RA4 combine to form a carbon-carbon double bond;
GA2 is absent or is —(CRA11RA12)n—;
XA3 is absent or is O, S, or NRA8;
each RA11, RA12, and RA8 is selected, independently, from H or optionally substituted C1-6 alkyl; and
n is 1 or 2;
or according to Formula (II-B)




where

RA5 is H;
each RA1, RA2, RA3, RA4, and RA6 is selected, independently, from H, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)—XA3—RA7, or RA1 and RA4 combine to form a carbon-carbon double bond;
each RA7 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each XA3 is, independently, absent, —O—, or —NRA8—,
or any pharmaceutically acceptable salt or solvate thereof or any stereoisomer thereof.
In some embodiments of Formula (II) (e.g., (II-A) and (II-B)), when one of RA1 and RA4 is H and the other is selected from H or CO2Et, and RA3 is unsubstituted phenyl, GA2-XA3—RA7 is not NHC6H5, NH(p-C6H4F), NH(p-C6H4OH), NH(p-C6H4OMe), NH(3-OH-4-C1-C6H4), —CH2(O-p-C6H4Me), —CH2(4-ethylpiperazinyl), —CH2S(2-phenyltetrazolyl), —CH2S(4-chlorophenyl), —CH2S(2-benzothiazolyl), —CH2S(2-(N-methylimidazolyl)), —CH2S(4,6-dimethylquinazolinyl), adamantyl, or optionally substituted oxiranyl.
Other compounds of Formula (II) include compounds of Formula (II-C):




where

each RA1, RA2, RA4, and RA6 is selected, independently, from H, —C(═O)—XA3—RA7, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RA1 and RA4 combine to form a carbon-carbon double bond;
each XA3 is, independently, absent, —O—, or —NRA8—,
each RA8 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CORA14, —CO2RA14, or —CONRA14RA15; and
each RA7, RA14 and RA15 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
In some embodiments of Formula (II-C), wherein when RA1 and RA4 combine to form a carbon-carbon double bond and RA2 is H, RA6 is not 4-chlorophenyl, 4-methoxyphenyl, or 4-(NHCO2tBu)phenyl. In other embodiments, when RA1 is H, RA4 is H or CO2Et, RA2 is unsubstituted phenyl, RA6 is not —C(═O)-(unsubstituted phenyl) or —C(═O)-(4-methylphenyl). In still other embodiments, when RA1 is H, RA4 is —C(═O)-(unsubstituted phenyl), RA2 is 4-chlorophenyl, RA6 is not CO2Et.
Compounds of Formula (II) (e.g., (II-A)-(II-C)) can be prepared according to methods known in the art. Exemplary methods of synthesis are shown in Schemes 2-5.




Scheme 2A shows a method that can be used to prepare pyrazole compounds of Formula (II). Terminal alkynes can be reacted with trimethylsilyldiazomethane (TMS-diazomethane) to afford compounds of Formula (II) where RA1 and RA4 combine to form a carbon-carbon double bond and R′ can be, for example, optionally substituted aryl or optionally substituted heteroaryl. Scheme 2B shows the preparation of Compound (13) using the method in Scheme 2A in which the aniline —NH2 group is protected prior to the reaction with TMS-diazomethane.




Scheme 3A depicts another method that can be used to synthesize pyrazoline compounds of Formula (II) according to methods described in J. Chem. Soc. 4686-90 (1952) and J. Med. Chem. 2127-2137 (2006). For example, substituted acroleins (e.g., R′ can be optionally substituted aryl or optionally substituted heteroaryl) can be treated with ethanolic hydrazine (Step (a)) to afford a pyrazoline intermediate. The pyrazoline can then be treated with an electrophilic compound having a suitable leaving group (e.g., alkyl halides, acid cholorides. or acid anhydrides) and an optional chemical promoter to afford N-substituted pyrazolines. Scheme 3B shows a method that can be used to prepare Compound (14) where an acid chloride can be used in Step (b) as shown.




Scheme 4 shows Compound (15) which can be prepared according to the procedure described in J. Am. Chem. Soc., page 165 (1943). This method can also be used to prepare other pyrazoline compounds of Formula (II), where RA6 is —C(═O)—RA7 and RA2 and RA7 are, independently, optionally substituted aryl or optionally substituted heteroaryl.




Scheme 5A depicts a method by which tetrazole compounds of Formula (II) can be prepared using methods described in WO2005115147 and in J. Med. Chem., 4686-90 (1952). For example, a tetrazole compound that includes a carboxylic acid group can be activated (e.g., treatment with PCl5 as in Step (a)) and subsequently treated with a nucleophile R′′ as in Step (b). Scheme 5B shows that 5-Phenyl-4,5-dihydro-1H-pyrazole can be used as the nucleophile in step (b′) to afford Compound (16).
Compounds of Formula (II) (e.g., (II-A) and (II-B) and compounds (13)-(16)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 3. Other compounds of Formula (II) are shown in Table 4. In some embodiments, Formula (II), (II-A), and (II-B) do not include any of compounds (13)-(26).










TABLE 3







Compound
Structure









(17)







 



(18)







 



(19)







 



(20)







 



(21)
























TABLE 4







Compound
Structure









(22)







 



(23)







 



(24)







 



(25)







 



(26)














Compounds of Formula (III)
Select compounds of the invention can be described by Formula (III)




where

RB1 is selected from H, optionally substituted C1-6 alkyl, —C(═O)RB18, —C(═O)ORB18, or —C(═O)NRB18RB19;
RB2 is selected from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, or optionally substituted C2-6 alkynyl;
each RB3 and RB4 is selected, independently from H, optionally substituted C1-6 alkyl, or RB3 and RB4 combine to form a bridging group having the structure —(CH2)n—(CRB13═CRB14)o—(CH2)p—;
each n, o, and p is, independently, 0 or 1;
each RB5, RB6, RB7, RB8, RB9, RB10, RB11, and RB12 is selected, independently, from H, halogen, —CN, —NO2, —N3, —RB13, —ORB13, —SRB13, —NRB13RB14, —C(═O)RB15, —C(═O)ORB15, —C(═O)NRB15RB16, —OC(═O)RB15, —OC(═O)ORB15, —OC(═O)NRB15RB16, —NRB15C(═O)RB15, —NRB15C(═O)ORB16, —NRB15C(═O)NRB16RB17, —C(═S)RB15, —C(═S)NRB15RB16, —NRB15C(═S)RB16, —NRB15C(═S)NRB16RB17, —C(═NRB13)NRB15RB16, —NRB15C(═NRB13)RB16, —NRB15C(═NRB13)NRB16RB17;
each RB13 and RB14 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)RB18, —C(═O)ORB18, or —C(═O)NRB18RB19;
each RB15, RB16, RB17, RB18, and RB19 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
where when each n, o, and p is 0, RB3 and RB4 combine to form a single bond,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
Select compounds of Formula (III) can also be described by Formula (III-A)




where RB1 is as described in Formula (III), RB2 is ethyl, ethenyl, or ethynyl and each RB9, RB10, RB11, and RB12 is selected, independently, from H and halogen,

or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RB1 is H.
Still other compounds of Formula (III) are described by Formula (III-B)




where RB1 is as described in Formula (III), RB2 is ethyl, ethenyl, or ethynyl and each RB9, RH10, RB11, and RB12 is selected, independently, from H and halogen,

or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, RB1 is H.
In some embodiments of Formula (III), RB1 is not H or CH3 when RB5, RB6, RB7, RB8, RB9, RB10, RB11, and RB12 are each H, RB2 is ethyl, ethenyl, ethynyl, propynyl, 2-haloethynyl, —(C≡CC(—OH)(CH3)2), and when RB3 and RB4 are each H or combine to form a bond, —CH2CH7— or —CH═CH—. In other embodiments of Formula (III), RB1 is not H when RB5, RB6, RB7, RB8, RB10, and RB11 are each H, at least one of RB9 or RB12 is fluoro, RB7 is ethynyl, and when RB3 and RB4 combine to form —CH7CH2—. In still other embodiments of Formula (III), RB1 is not H when RB6, RB7, RB8, RB10, and RB11 are H and one or two of RB6, RB8, RB10, and RB12 is halogen, nitro, or methyl.




Scheme 6A depicts a method by which compounds of Formula (III) can be prepared. A ketone derivative can be treated with an anionic carbon nucleophile (e.g., lithium trimethylsilylacetylide formed in step (a)). The resulting alkoxide can be trapped using a protic quench or by the addition of an electrophilic reagent. Finally, the trimethylsilyl group can be deprotected using basic conditions. If desired, the alkyne group can be further manipulated (e.g., subjected to hydrogenation conditions to afford the corresponding alkene or alkyl group or treated with a metal catalyst/and organic electrophile in cross-coupling reactions). Scheme 6B shows Compound (27), which can be prepared using these conditions.
Compounds of Formula (III) (e.g., (III-A) and (III-B) and compound (27)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 5. Other compounds of Formula (III) include Compounds (35)-(36), (39)-(40), and (42)-(47) shown in Table 6. In some embodiments, Formula (III) does not include any of Compounds (27)-(33), (35)-(36), (39)-(40), or (42)-(47).










TABLE 5







Compound
Structure









(28)







 



(29)







 



(30)







 



(31)







 



(32)







 



(33)
























TABLE 6







Compound
Structure









(34)







 



(35)







 



(36)







 



(37)







 



(38)







 



(39)







 



(40)







 



(41)







 



(42)







 



(43)







 



(44)







 



(45)







 



(46)







 



(47)














Compounds of Formula (IV)
Still other compounds can be described according to Formula (IV)




where

each RC1, RC2, and RC3 is selected, independently, from H, optionally substituted C1-6 alkyl, —Y—RC7, or RC1 and RC2 combine to form a (═O) or a (═S) group, or RC1 and RC3 combine to form a carbon-nitrogen double bond;
RC4 is selected from H, halogen, —CN, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or —C(═O)ZRC8,
each RC5 and RC6 is selected, independently, from H, optionally substituted C1-6 alkyl, or RC1 and RC2 combine to form an optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RC7, RC8, RC9, RC10, RC11, and RC12 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
X is —CRC11═CRC12—, O, S, or NRC9;
Y is, independently, a single bond, (CRC8RC9)n, O, S, or NRC10;
Z is a single bond, O, S, or NRC10;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (IV), when X is S, RC1 and RC2 combine to form a (═O) group, RC4 is H, and RC5 and RC6 combine to form unsubstituted cyclopentyl, RC3 is not —CH2—RC7, where RC7 is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted 8-quinolyl, unsubstituted 2-oxoquinolyl, or phenyl having 1 or 2 substituents selected from F, OMe, Me, CN, or Cl. In other embodiments of Formula (IV), when X is S, RC1 and RC2 combine to form a (═O) group, RC4 is H, and RC5 and RC6 are each Me, RC3 is not —CH2—RC7, where RC7 is unsubstituted phenyl. In other embodiments of Formula (IV), when X is CH═CH, RC1 and RC2 combine to form a (═O) group, Re4, RC5 and RC6 are H, RC3 is not —CH2(4-halophenyl).
Select compounds of Formula (IV) can also be described by Formula (IV-A)




where X, RC1, RC2, RC3, and RC4 are as defined for Formula (IV) and n is an integer between 0-3,

or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.




Scheme 7A depicts a method by which compounds of Formula (IV) (e.g., compounds of Formula (IV-A)) can be prepared. A heterocyclic derivative can be deprotonated using a base such as NaH and subsequently treated with an electrophile (e.g., an alkyl halide such as benzyl bromide, an acid chloride, or an acid anhydride) to afford a compound of Formula (IV) such as Compound (48) shown in Scheme 7B.
Compounds of Formula (IV) (e.g., (IV-A) and Compound (48)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 7. In some embodiments, Formula (IV) does not include any of Compounds (48)-(57).










TABLE 7







Compound
Structure









(49)







 



(50)







 



(51)







 



(52)







 



(53)







 



(54)







 



(55)







 



(56)







 



(57)














Compounds of Formula (V)
Other compounds of the invention can be described by Formula (V)




where

each XD1 and XD2 is selected, independently, from O, S, NRD5, or CRD6RD7;
YD1 is selected from a covalent bond, —C(═O)—, —S(═O)—, or —S(═O)2—;
YD2 is selected from a covalent bond, —C(═O)—, —OC(═O)—, —NRD8C(═O)—, —S(═O)—, —S(═O)2—, —OS(═O)—, —OS(═O)2—, —NRD8S(═O)—, —NRD8S(═O)2—, or —C(═S)—;
A is selected from optionally substituted aryl or optionally substituted heteroaryl;
GD1 is selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, ORD9, or NRD9RD10;
each RD1, RD2, RD3, RD4, RD6, RD7, is selected, independently, from H, halogen, CN, NC, N3, NO2, ORD11, SRD11, NRD11RD12, —CORD13, —CO2RD13, —CONRD13RD14, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RD1 and RD4, or RD1 and RD5, or RD1 and RD6, or RD3 and RD5, or RD3 and RD6 combine to form a double bond;
each RD5, RD8, RD9, RD10, RD13, RD14, RD15, and RD16 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RD9 and RD10 combine to form a heterocyclyl;
each RD11 and RD12 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CORD15—CO2RD15, —CONRD15RD16, —S(═O)RD15, —S(O)ORD15, —S(═O)NRD15RD16, —S(═O)2RD15, —S(═O)2ORD15, —S(═O)2NRD15RD16;
where YD1 and YD2 are each covalently bound to a carbon center in A;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
Still other compounds of Formula (V) can be described by Formula (V-A)




where

each YD1 and YD2 is selected, independently, from —C(═O)— or —S(═O)2—;
A is phenyl having 0, 1, 2, 3, or 4 additional substituents;
RD2 and RD3 are selected, independently from H, halogen, CN, NC, N3, NO2, —CORD13, —CO2RD13, —CONRD13RD14, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RD5, RD9, RD10, RD13, and RD14 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RD9 and RD10 combine to form a heterocyclyl; or by Formula (V-B)




where

each RD2, RD3, RD17, RD18, RD19, and RD20 is selected, independently from H, halogen, CN, NC, N3, NO2, —CORD13, —CO2RD13, —CONRD13RD14, optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each RD9 and RD10 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, or optionally substituted aryl, or RD9 and RD10 combine to form a heterocyclyl; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (V), when RD1 and RD4 combine to form a double bond, RD2 and RD3 are H, XD1 is NH, XD2 is S, YD1 is —(C═O)—, YD2 is —(SO2)—, GD1 is —N(Et)2, and A is phenyl having no additional substituents, YD1 and YD2 are not para to each other.




Compounds of Formula (V) (e.g., compounds of Formula (V-A) or (V-B)) can be prepared, for example, by treating an aryl or heteroaryl compound that has two electrophilic groups successively with nucleophilic reagents to afford the desired compound. For example, as shown in Scheme 8 and using procedures adapted from Heterocyclic Communications, 12(6): 453-456 (2006) and Organic Synthesis, Collective Vol. 6, page 818, the difunctional benzene derivative 4-CO2Hphenylsulfonyl chloride can be treated with a nucleophile such as diethylamine to afford the corresponding sulfonamide. This compound can then be esterified prior to treatment with a second nucleophile (e.g., methanolic ammonia). Finally, the compound afforded by step (c) can then be condensed with a carbonyl-containing compound to afford compounds of Formula (V) such as Compound (58).
Compounds of Formula (V) (e.g., (V-A) and (V-B) and compound (34)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). In some embodiments, Formulas (V), (V-A), and (V-B) do not include Compounds (58).
Compounds of Formula (VI)
Still other compounds of the invention can be described by Formula (VI)




where

each XE1 and XE3 is selected, independently, from N or CRE4;
each XE4 and XE5 is selected, independently, from O, S, or NRE5;
XE2 is selected from O, S, or N;
each ZE1, ZE2, and ZE3 is selected, independently, from a single bond, —(CRE6RE7)n—, —C(═O)—, or —S(═O)2—, or ZE1—RE1 and ZE2—RE2 combine to form a double bond;
each RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
p is 0 or 1; and
n is an integer between 1-6; and
where when XE2 is O or S, ZE2—RE2 is not present;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, each RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl
In some embodiments, RE3 is selected from substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments of Formula (VI), when p is 0, XE1 is CH, —ZE1—RE1 is —CH2(indol-3-yl), XE4 and XE5 are 0, and XE2—ZE2—RE2 is NH, XE3—ZE3—RE3 is not —NCH2(p-ClC6H4) or —NCH2CH2O(p-FC6H4).
In other embodiments, when XE1—ZE1—RE1 is NH, XE2—ZE2 is CH—CH2, RE2 is unsubstituted 3-indolyl, p is 0, XE4 is S, XE5 is O, XE3 is N, and ZE3 is CH2, RE3 is not —CH2CH2(4-morpholine).
In still other embodiments, when XE1—ZH—RE1 is NH, XE2—ZE2 is CH—CH2, RE2 is unsubstituted or substituted 3-indolyl, p is 0 or 1, both XE4 and XE5 are O or XE4 is S and XE5 is O, XE3 is N, and ZE3 is CH2, RE3 is not H, unsubstituted C1-6 alkyl, or —CH2CH═CH2.
In any of the compounds of Formula (VI) described herein (e.g., any compound having a structure according to Formulas (VI), (VI-A), (VI-B), (VI-C), or (VI-D)), the RE3 group can be unsubstituted. In some embodiments, a substituted RE3 group includes 1, 2, 3, 4, or 5 substituents selected from, for example, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, azido(—N3), alkoxy (—OR′), amido (—NR′C(═O)R′′ or —C(═O)NRR′), amino (—NRR′), carbamoyl (—OC(═O)NR′R′′ or —NRC(═O)OR′), hydroxy (—OH), or isocyano (—NC), where each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl. In other embodiments, the substituted RE3 group includes 1, 2, 3, or 4 substituents that are electron donating groups (e.g., hydroxy, C1-6 alkoxy, C1-6 alkyl, and amino groups).
Certain compounds of Formula (VI) may be described by Formula (VI-A) or Formula (VI-B)




wherein

each ZE2 and ZE3 is selected, independently, from a single bond, —(CRE6RE7)n—, —C(═O)—, or RE1 and ZE2—RE2 combine to form a double bond;
each RE1, RE2, RE3, and RE4 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RE6 and RE7 is selected, independently, from H or optionally substituted C1-6 alkyl; and
n is an integer between 1-6;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments, each RE1, RE2, RE3, and RE4 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments, RE3 is selected from substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
In some embodiments of Formula (VI-A), when RE1 and RE4 are H, ZE2 and ZE3 are each CH2, and RE2 is unsubstituted 3-indolyl, RE3 is not 4-chlorophenyl.
In certain embodiments, the compounds of Formula (VI) are described by the following formula:




where

each XE4 and XE5 is, independently, O or S;
XE2 is O or N;
each ZE2 and ZE3 is selected, independently, from a single bond or —(CRE6RE7)n—;
each RE2 and RE3 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
each R3 and R4 is, independently, H, halogen, or optionally substituted C1-6 alkyl;
each R5, R6, R7, R8, and R9 is selected, independently, from H, halogen, CN, NO2, OR13, NR13R14, COR15, CO2R15, optionally substituted C1-6 alkyl, or optionally substituted aryl;
R10 is selected from H, halogen, CN, NO2, OR13, NR13R14, COR15, CO2R15, optionally substituted C1-6 alkyl, optionally substituted aryl, optionally substituted alkenyl, or optionally substituted alkynyl;
each R13 and R14 is selected, independently, from H, COR16, CO2R16, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each R11, R12, R15, and R16 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
where, independently, n is 0, 1, 2, 3, 4, or 5, and p is 0 or 1;
or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
In some embodiments, p is 0.
In some embodiments, RE3 is selected from substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.
Select compounds of Formula (VI-C) can also be described by Formula (VI-D):




where

XE5 is O or S;
—ZE3—RE3 is optionally substituted C1-4 alkaryl;
each R3, R4, and R10 is, independently, H or optionally substituted C1-6 alkyl;
R9 is H, halogen, CN, NO2, OR13, NR13R14, COR15, CO2R15, or optionally substituted C1-6 alkyl;
each R13 and R14 is selected, independently, from H, COR16, CO2R16, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each R11, R12, R15, and R16 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
where n is 1 or 2;
or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
In some embodiments, the compound has a structure according to the following formula:




or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof, where n, ZE3, RE3, R3, R4, R9, and R10 are as defined for Formula (IV-D).

In the compounds of the invention, the sp3-hybridized carbon to which G is attached (e.g., the chiral center marked with an asterisk in any of Formulas (VI-A), (VI-B-1), (VI-B-2), (VI-C), (VI-D), or (VI-E)) can have the (R)- or the (S)-configuration. For example, compounds of the invention include




or any pharmaceutically acceptable salt or solvate thereof.
In any embodiment of Formulas (VI-C), (VI-D), or (VI-E), n=1 and R3 and R4 are each H. In another embodiment, R10 is H or CH3. In still other embodiments, R9 is H, halogen, optionally substituted C1-6 alkyl, OH, or —O-(optionally substituted C1-6 alkyl).
In any embodiment of Formulas (VI-C), (VI-D), or (VI-E), —ZE3—RE3 is optionally substituted benzyl. In one embodiment, —ZE3—RE3 is unsubstituted benzyl. In another embodiment, —ZE3—RE3 is benzyl having 1, 2, 3, 4, or 5 substituents. In some embodiments, the substituents are selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, azido(—N3), alkoxy (—OR′), amido (—NR′C(═O)R′′ or —C(═O)NRR′), amino (—NRR′), carbamoyl (—OC(═O)NR′R′′ or —NRC(═O)OR′), hydroxy (—OH), and isocyano (—NC), as described herein. In a further embodiment, —ZE3—RE3 is CH2— (p-XC6H4), where X is halogen. In some embodiments, X is F or Cl.
In any of the embodiments described herein, one or both of —ZE3 and RE3 do not include substituents selected from the group consisting of: halogen (e.g., F, Cl, Br, or I); nitro (—NO2), cyano (—CN), acyloxy(—OC(═O)R′), acyl (—C(═O)R′), carboxylic acid (—CO2H), carboxylic ester (—CO2R′), sulfonate (—S(═O)2OR), sulfonamide (—S(═O)2NRR′ or —NRS(═O)2R′), or sulfonyl (—S(═O)2R), where each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, as described herein.




Compounds of Formula (VI) (e.g., compounds of Formulas (VI-A), (VI-B), (VI-C), or (VI-D)) can be prepared, for example, by treating hydantoin compound that has, for example, a substituent R at the 5-position with a base followed by trapping with an electrophilic reagent (Scheme 9A). For example, Scheme 9B shows that the synthesis of Compound (59) can be achieved by the use of 4-chlorobenzylbromide as the electrophile.
In some embodiments, Formula (VI) (e.g., compounds of Formulas (VI-A), (VI-B), (VI-C), or (VI-D)) does not include any of the compounds or formulas disclosed in U.S. Pat. Nos. 6,756,394 and 7,253,201, in U.S. Patent Publication No. 20050119260, and in pending U.S. application Ser. Nos. 12/077,320 and 12/086,792, each of which is hereby incorporated by reference.
Compounds of Formula (VI) (e.g., (VI-A)-(VI-D) and compound (59)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
In some embodiments, Formula (VI) does not include compound (59).
Compounds of Formula (VII)
Still other compounds can be described according to Formula (VII)




where

ZF1 is selected from a single bond, —(CRF10RF11)n—, —C(═O)—, —S(═O)—, or —S(═O)2—;
each RF1, RF2, RF4, RF10, RF11, RF12, and RF13, is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RF2 and RF4 combine to form a carbon-carbon double bond;
each RF3 and RF5 is selected, independently, from H, halogen, CN, CO2RF12, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each RF6, RF7, RF8, and RF9 is selected, independently, from H, halogen, CN, NC, N3, NO2, ORF12, SRF12, NRF12RF13, —CORF12, —CO2 F12, —CONRF12RF13, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
where n is an integer between 1-6;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
Certain compounds of Formula (VII) can also be described by Formula (VII-A)




where

ZF1 is selected from a single bond, —(CH2)—, —C(═O)—, or —S(═O)2—;
RF1 is selected from H, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
RF2 and RF4 are each H, or RF2 and RF4 combine to form a carbon-carbon double bond;
each RF6, RF7, RF8, and RF9 is selected, independently, from H, halogen, CN, NC, N3, NO2, ORF12, SRF12, NRF12RF13, —CORF12, —CO2 F12, —CONRF12RF13, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each RF12 and RF13, is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (VII-A), when RF2, RF4, RF6, RF7, RF8, and RF9 are each H and ZF1 is —C(═O)—, RF1 is not -(unsubstituted 1,4-benzodioxane) or —CH2—(O-(unsubstituted phenyl)).




Scheme 10 provides a method by which compounds of Formula (VII) such as Compound (60) can be prepared. For example, a nucleophilic compound such as indoline can be treated with an electrophile (e.g., a compound containing a carboxylic acid) in the presence of an optional promoter such as DEAD/PPh3 to afford the requisite compound. Another compound of Formula (VIII) is Compound (61) (Scheme 11).




Compounds of Formula (VII) (e.g., (VII-A) and compound (60)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). In some embodiments, Formulas (VII) and (VII-A) do not include compounds (60) or (61).
Compounds of Formula (VIII)
Still other compounds useful in the invention are described by Formula (VIII):




where

XG1 is selected from —O—, —N—, or —(CRG9RG10)n—;
XG2 and XG3 are selected, independently, from N or CRG11;
each RG1, RG2, RG3, RG4, RG5, RG6, RG7, RG8, RG9, RG10, and RG11 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RG1 and RG2, or RG3 and RG4, or RG5 and RG6, or RG7 and RG8 combine to form an optionally substituted cycloalkyl or heterocyclyl; and
n is 1 or 2;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
Select compounds of Formula (VIII) can also be described by Formula (VIII-A):




wherein each RG1, RG2, RG5, and RG6 is selected, independently, from H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or RG1 and RG2, or RG5 and RG6 combine to form an optionally substituted cycloalkyl or heterocyclyl,

or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
In some embodiments of Formula (VIII-A), when RG1 is unsubstituted phenyl and RG2 is H, RG5 and RG6 do not combine to form unsubstituted cyclopentyl,
Methods by which compounds of Formula (VIII) (e.g., compounds of Formula (VIII-A) can be prepared are known in the art. For example, Compound (62) shown in Scheme 12, can be prepared according to methods described in Synthesis, pages 771-783 (2002).




Compounds of Formula (VIII) (e.g., (VIII-A) and compound (62)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
In some embodiments, Formulas (VIII) and (VIII-A) do not include compound (62).
Additional Inhibitors of Necroptosis
Other compounds useful in the compositions, kits, and methods of the invention are described in U.S. Pat. Nos. 6,756,394 and 7,253,201, in U.S. Patent Publication No. 20050119260, and in pending U.S. application Ser. Nos. 12/077,320 and 12/086,792, each of which is hereby incorporated by reference. In addition to the compounds described by Formulas (I)-(VIII), other inhibitors of necroptosis include, but are not limited to, the structures depicted in Table 8, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.








TABLE 8





Compound
Structure







(63)






 


(64)






 


(65)






 


(66)






 


(67)






 


(68)






 


(69)






 


(70)













Pharmaceutical Compositions

The necrostatins described herein (e.g., compounds of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) can be formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo. Accordingly, the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable excipient. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003-20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999.
The compounds may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention. In accordance with the methods of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.
Pharmaceutically Acceptable Excipients
Pharmaceutically acceptable excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
Oral Administration
Any of the compounds described herein (e.g., compounds of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
Parenteral Administration
A compound may also be administered parenterally. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe.
Nasal Administration
Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer.
Buccal or Sublingual Administration
Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, or gelatin and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.
The compounds of the invention may be administered to an animal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.
Dosage Amounts
The amount of active ingredient (e.g., a compound of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) in the compositions of the invention can be varied. One skilled in the art will appreciate that the exact individual dosages may be adjusted somewhat depending upon a variety of factors, including the protein being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the nature of the subject's conditions, and the age, weight, health, and gender of the patient. Generally, dosage levels of between 0.1 μg/kg to 100 mg/kg of body weight are administered daily as a single dose or divided into multiple doses. Desirably, the general dosage range is between 250 μg/kg to 5.0 mg/kg of body weight per day. Wide variations in the needed dosage are to be expected in view of the differing efficiencies of the various routes of administration. For instance, oral administration generally would be expected to require higher dosage levels than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, which are well known in the art. In general, the precise therapeutically effective dosage will be determined by the attending physician in consideration of the above identified factors.
Therapeutic Uses and Screening Methods
The compounds disclosed herein (e.g., compounds of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) can be used to treat disorders where necroptosis is likely to play a substantial role (e.g., cerebral ischemia, traumatic brain injury, a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor). Compounds of the invention can also be used in screening methods to identify targets of necroptosis and to identify additional inhibitors of necroptosis, as well as in assay development.
Compounds disclosed herein can be evaluated for their pharmacological properties in animal models of disease. The compounds identified to decrease necrosis or necroptosis may be structurally modified and subsequently used to decrease necrosis or necroptosis, or to treat a subject with a condition in which necrosis or necroptosis occurs. The methods used to generate structural derivatives of the small molecules that decrease necrosis or necroptosis are readily known to those skilled in the fields of organic and medicinal chemistry.
Therapy according to the invention may be performed alone or in conjunction with another therapy, for example in combination with apoptosis inhibitors, and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the therapy depends on the age and condition of the patient, as well as how the patient responds to the treatment. Additionally, a person having a greater risk of developing a condition may receive prophylactic treatment to inhibit or delay symptoms of the disease.
In some embodiments, the compounds and methods of the invention can be used to treat any of the following disorders where necroptosis is likely to play a substantial role: a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, and any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
Conditions Caused by Alteration in Cell Proliferation, Differentiation, or Intracellular Signalling
Conditions in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor include cancer and infection, e.g., by viruses (e.g., acute, latent and persistent), bacteria, fungi, or other microbes.
Exemplary viruses are human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV)5 human herpesviruses (HHV), herpes simplex viruses (HSV), human T-Cell leukemia viruses (HTLV)5 Varicella-Zoster virus (VZV), measles virus, papovaviruses (JC and BK), hepatitis viruses, adenovirus, parvoviruses, and human papillomaviruses. Exemplary diseases caused by viral infection include, but are not limited to, chicken pox, Cytomegalovirus infections, genital herpes, Hepatitis B and C, influenza, and shingles.
Exemplary bacteria include, but are not limited to Campylobacter jejuni, Enterobacter species, Enterococcus faecium, Enterococcus faecalis, Escherichia coli (e.g., E. coli O157:H7), Group A streptococci, Haemophilus influenzae, Helicobacter pylori, listeria, Mycobacterium tuberculosis, Pseudomonas aeruginosa, S. pneumoniae, Salmonella, Shigella, Staphylococcus aureus, and Staphylococcus epidermidis. Exemplary diseases caused by bacterial infection include, but are not limited to, anthrax, cholera, diphtheria, foodborne illnesses, leprosy, meningitis, peptic ulcer disease, pneumonia, sepsis, tetanus, tuberculosis, typhoid fever, and urinary tract infection.
Neurodegenerative Diseases
Exemplary neurodegenerative diseases are Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, HIV-associated dementia, cerebral ischemia, amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease, Menke's disease, Wilson's disease, Creutzfeldt-Jakob disease, and Fahr disease. Exemplary muscular dystrophies or related diseases are Becker's muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy, limb-girdle muscular dystrophy, Landouzy-Dejerine muscular dystrophy, facioscapulohumeral muscular dystrophy (Steinert's disease), myotonia congenita, Thomsen's disease, and Pompe's disease. Muscle wasting can be associated with cancer, AIDS, congestive heart failure, and chronic obstructive pulmonary disease, as well as include necrotizing myopathy of intensive care.
Compounds and methods of the invention can additionally be used to boost the immune system, whether or not the patient being treated has an immunocompromising condition. For example, the compounds described herein can be used in a method to strengthen the immune system during immunization, e.g., by functioning as an adjuvant, or by being combined with an adjuvant.
Kits
Any of the compounds or pharmaceutical compositions of the invention (e.g., those that include a compound of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) can be used together with a set of instructions, i.e., to form a kit. The kit may include instructions for use of the compounds of the invention in a screening method or as a therapy as described herein.
The following non-limiting examples are illustrative of the present invention.
EXAMPLES
Example 1
Determination of Necroptosis Inhibitory Activity
Evaluation of necroptosis inhibitory activity was performed using a FADD-deficient variant of human Jurkat T cells or with L929 cells treated with TNF-α as previously described (Degterev et al., Nat. Chem. Biol. 1:112 (2005) and Jagtap et al., J. Med. Chem. 50: 1886 (2007)). Utilizing these conditions the cells efficiently underwent necroptosis. For EC50 value determinations, cells were treated with 10 ng/mL of human TNF-α in the presence of increasing concentration of test compounds for 24 hours followed by ATP-based viability assessment.
ATP-based viability assessment: Briefly, necroptosis activity was performed using a FADD-deficient variant of human Jurkat T cells or L929 cells treated with TNF-α. For EC50 value determinations, cells (500,000 cells/mL, 100 μL per well in a 96-well plate) were treated with 10 ng/mL of human TNF-α in the presence of increasing concentration of test compounds for 24 hours at 37° C. in a humidified incubator with 5% CO2 followed by ATP-based viability assessment. Stock solutions (30 mM) in DMSO were initially prepared and then diluted with DMSO to give testing solutions, which were added to each test well. The final DMSO concentration was 0.5%. Eleven compound test concentrations (0.030-100 μM) were used. Each concentration was done in duplicate.
Cell viability assessments were performed using a commercial luminescent ATP-based assay kit (CellTiter-Glo, Promega, Madison, Wis.) according to the manufacturer's instructions. Briefly, 40 μL of the cell lysis/ATP detection reagent was added to each well. Plates were incubated on a rocking platform for 10 minutes at room temperature and luminescence was measured using a Wallac Victor 3 plate-reader (Perkin Elmer, Wellesley, Mass.). Cell viability was expressed as a ratio of the signal in the well treated with TNF-α and compound to the signal in the well treated with compound alone. This was done to account for nonspecific toxicity, which in most cases was <10%. EC50 values were calculated using nonlinear regression analysis of sigmoid dose-response (variable slope) curves from plots of log [I] verses viability values.
Results obtained using these procedures are shown in Table 9.











TABLE 9







EC50

LD50


Compound

Fadd −/−
EC50
Fadd −/−


no.
Structure
Jurkat
L929
Jurkat



















 (1)




0.4769
0.1971
>2000


 


 (2)




0.7690
—
—


 


 (3)




0.8232
—
—


 


 (4)




0.3540
—
—


 


 (5)




24.98
—
—


 


 (6)




Partial  activity
—
—


 


 (7)




2.379
—
—


 


 (8)




inactive




 


 (9)




inactive




 


(10)




inactive




 


(11)




inactive




 


(12)




inactive




 


(13)




5.379
0.89
539.4


 


(14)




0.4101
4.202
396.9


 


(15)




0.3688
4.02
799.5


 


(16)




0.6289
72.97
247.7


 


(17)




inconclusive
—
—


 


(18)




0.4101
—
—


 


(19)




0.3688
—
—


 


(20)




3.211
—
—


 


(21)




1.557
—
—


 


(22)




Inactive




 


(23)




Inactive




 


(24)




Inactive




 


(25)




Inactive




 


(26)




Inactive




 


(27)




3.227
0.659
541.3


 


(28)




2.98
—
—


 


(29)




31.78
—
—


 


(30)




5.833
—
—


 


(31)




2.954
—
—


 


(32)




2.002
—
—


 


(33)




4.788
—
—


 


(34)




Inactive




 


(35)




Inactive




 


(36)




Inactive




 


(37)




Inactive




 


(38)




Inactive




 


(39)




Inactive




 


(40)




Inactive




 


(41)




Inactive




 


(42)




Inactive




 


(43)




Inactive




 


(44)




Inactive




 


(45)




Inactive




 


(46)




Inactive




 


(47)




Inactive




 


(48)




0.2161
8.66
188.9


 


(49)




3.803
—
—


 


(50)




>30
—
—


 


(51)




10.88
—
—


 


(52)




3.046
—
—


 


(53)




>30
—
—


 


(54)




0.8606
—
—


 


(55)




>30
—
—


 


(56)




>30
—
—


 


(57)




0.9363
—
—


 


(58)




8.958
1.11
>2000


 


(59)




0.3431
7.458
115.7


 


(60)




0.6289
23.04
356.5


 


(61)




Inactive




 


(62)




0.6683
10.09
754


 


(63)




2.364
13.7
1364


 


(64)




14.14
Inactive
1788


 


(65)




3.621
Inactive
138.6


 


(66)




2.616
47.12
256.8


 


(67)




2.245
10.02
697.8


 


(68)




1.633
Inactive
252.3


 


(69)




7.724
Inactive
1571


 


(70)




0.9077
Inactive
>2000









All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
Other embodiments are within the claims.

## Claims

1. A compound having the following structure:




wherein:
XE5 is O or S;
RE3 is optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R9 is halogen, CN, NO2, OR13, NR13R14, COR15, CO2R15, or optionally substituted C1-6 alkyl;
each R13 and R14 is, independently, H, COR16, CO2R16, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each R15 and R16 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

2. The compound of claim 1, wherein said compound has a structure according to the following formula:




wherein
RE3 is optionally substituted aryl or optionally substituted heteroaryl; and
R9 is halogen;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

3. The compound of claim 2, wherein RE3 is unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

4. The compound of claim 3, wherein RE3 is unsubstituted aryl or heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

5. The compound of claim 2, wherein RE3 is substituted C3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

6. The compound of claim 5, wherein RE3 is substituted aryl or substituted heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

7. The compound of claim 6, wherein RE3 is substituted phenyl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

8. The compound of claim 7, wherein said substituted phenyl is substituted with at least one halogen,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

9. The compound of claim 7, wherein said substituted phenyl is substituted with 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N3, —OR′, —NR′C(═O)R′′, —C(═O)NRR′, —NRR′, —OC(═O)NR′R′′, —NRC(═O)OR′, —OH, and —NC, wherein each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

10. The compound of claim 2, wherein the stereocenter marked by the asterisk has the (R)-configuration,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

11. The compound of claim 2, wherein the stereocenter marked by the asterisk has the (S)-configuration,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

12. A pharmaceutical composition comprising the compound of claim 1 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and a pharmaceutically acceptable excipient.

13. The compound of claim 1, wherein said compound has a structure according to the following formula:




wherein
RE3 is optionally substituted aryl or optionally substituted heteroaryl; and
R9 is halogen;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

14. The compound of claim 13, wherein RE3 is unsubstituted C3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

15. The compound of claim 14, wherein RE3 is unsubstituted aryl or heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

16. The compound of claim 13, wherein RE3 is substituted C3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl;
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

17. The compound of claim 16, wherein RE3 is substituted aryl or substituted heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

18. The compound of claim 17, wherein RE3 is substituted phenyl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

19. The compound of claim 18, wherein said substituted phenyl is substituted with at least one halogen,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

20. The compound of claim 18, wherein said substituted phenyl is substituted with 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N3, —OR′, —NR′C(═O)R′′, —C(═O)NRR′, —NRR′, —OC(═O)NR′R′′, —NRC(═O)OR′, —OH, and —NC, wherein each R or R′ is selected, independently, from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

21. The compound of claim 13, wherein the stereocenter marked by the asterisk has the (R)-configuration,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

22. The compound of claim 13, wherein the stereocenter marked by the asterisk has the (S)-configuration,
or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.

23. A pharmaceutical composition comprising the compound of claim 2 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and a pharmaceutically acceptable excipient.

24. A pharmaceutical composition comprising the compound of claim 13 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and a pharmaceutically acceptable excipient.

25. A method of treating a condition in a subject, said method comprising administering the compound of claim 1 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.

26. The method of claim 25, wherein said condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.

27. A method of treating a condition in a subject, said method comprising administering the compound of claim 2 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.

28. The method of claim 27, wherein said condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.

29. A method of treating a condition in a subject, said method comprising administering the compound of claim 13 or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.

30. The method of claim 29, wherein said condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.